955 results about "Aspirin" patented technology

A liquid composition applied transdermally for relief of pain comprising alcohol in an amount by weight of about 57 to about 91 percent; glycerin in an amount by weight of about 1 to about 12 percent; an analgesic agent in an amount by weight of about 2 to about 28 percent, the analgesic agent comprising a derivative of salicylic acid; methylsulfonylmethane in an amount by weight of about 0.02 to 5 percent; and emu oil in an amount by weight of about 0.01 to 3 percent, the liquid composition permeating skin to relieve pain. The composition further comprising, as an additional feature, aloe vera in an amount by weight of at least about 0.05 percent and having an amount by weight of about 0.05 to 4 percent. The composition features transdermal pain relief such that a patient can apply the analgesic agent directly to an area of pain without such side effects as stomach irritation which is normally associated with aspirin. The composition may be sprayed or rolled directly onto the painful area. Because of the unique formula, the composition is safe to vital internal organs, requires no mixing before use, and is shelf stable for marketing purposes.

A bottle cap is adapted to retain a quantity of an additive, such as for example aspirin or the like. The additive is retained in an isolated condition within a sealed chamber or within a bladder inside the bottle cap but in fluid communication with the liquid within the bottle, such as water. Means are provided to breech the seal of the chamber or the bladder, thereby releasing some or all of the additive retained within the bottle cap.

The present invention provides a therapeutic method for treating gastric lesions, including administration to a patient in need thereof of an effective amount of an A_2A adenosine receptor agonist. The A_2A adenosine receptor agonist can be a compound of formula (I) as disclosed herein. The invention further provides a therapeutic method for treating the patient with an A_2A adenosine receptor agonist, optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor. In one embodiment, the gastric lesions are caused by, or aggravated by, the use of NSAIDS such as, for example, aspirin.

Compounds comprising multi-vitamins, zinc and an anti-platelet aggregating agent for the treatment of atherosclerotic cardiovascular disease (ASCVD) are disclosed. The compounds are provided in dosage form, and preferably include selected amounts of ascorbic acid, folic acid, vitamin E, vitamin B6 and vitamin B12. The anti-platelet aggregating agent preferably comprises aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment of ASCVD, and possess extended shelf lives.

The invention relates to a dual-emission ratio-type quantum dot fluorescence probe for visual detection of aspirin, a preparation method and an application thereof and belongs to the technical field of preparation of material and detection of content of medicines. The preparation method of the probe includes following steps: preparing a precursor NaHTe solution from sodium borohydride, tellurium powder and water under an ultrasonic environment; adding the precursor to an aqueous solution of CdCl2.2.5H2O in the presence of thioglycollic acid; carrying out a reflux reaction with a nitrogen protecting condition to obtain required green fluorescence quantum dot and red fluorescence quantum dot; by means of a sol-gel method, wrapping the red fluorescence quantum dot with silicon spheres with amino group being connected; dispersing a green fluorescence quantum dot solution and the red fluorescence quantum dot wrapped with the silicon spheres in an MES buffer solution with addition of an EDC/NHS solution; and carrying out a reaction at room temperature in a dark place to obtain the dual-emission ratio-type quantum dot fluorescence probe. The dual-emission ratio-type quantum dot fluorescence probe is used in detection of the content of the aspirin through fluorescence quantitation and visualized analysis. The quantum dot fluorescence probe is quite good in optical performance and stability and has a capability of visualizedly detecting the aspirin.

The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

The invention discloses a plant rooting aid. The plant rooting aid comprises the following components in percentage by weight: 36.44% of distilled water, 1% of rice vinegar, 0.05% of aspirin, 12% of vitamin B12, 10% of cane sugar, 20% of honey, 20% of a withy leaching agent, 0.5% of potassium permanganate and 0.01% of acetic acid. Compared with the prior art, The plant rooting aid is mostly prepared from natural materials, low in cost, very low in content of chemical agents, capable of strengthening nutrition of plants and promoting the rooting of the plants and has popularization and application values.

An auxiliary container (10) adapted for unintrusive coupling with a conventional medication container (12), such as pill bottle, cream tube, or spray can, wherein the auxiliary container (10) provides an independent storage space (26) which does not require breaking a seal of, removing, or replacing an existing lid (70) or cap of the conventional container (12). In one contemplated use, for example, the auxiliary container (10) is used to store small doses of a supplementary medication (14), such as aspirin, in close association with a primary medication (e.g., a heart medicine such as nitroglycerine), such that both are conveniently available and accessible for immediate use. In a preferred first embodiment, the auxiliary container (10) broadly comprises a body (16); a lid (18); a closure mechanism (20); and a coupling mechanism (22).

The invention discloses a liposome preparation of sodium aspirin and sodium pravastatin. The liposome is mainly prepared from the following components in part by weight: 20 to 40 parts of sodium aspirin, 81 parts of sodium pravastatin, 200 to 1,000 parts of hydrogenated soybean phosphatidylcholine, 50 to 500 parts of cholesterol and 100 to 400 parts of poloxamer 188. The invention also discloses a solid preparation of a sodium aspirin and sodium pravastatin medicinal composition, which is prepared from the liposome preparation of sodium aspirin and sodium pravastatin, and other excipients usually used pharmaceutically. The quality of the preparation is improved and the toxic and side effects are reduced.

A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient.

The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.